دورية أكاديمية

Skeletal abnormalities secondary to antenatal etidronate treatment for suspected generalised arterial calcification of infancy

التفاصيل البيبلوغرافية
العنوان: Skeletal abnormalities secondary to antenatal etidronate treatment for suspected generalised arterial calcification of infancy
المؤلفون: Neha Agarwal, Umber Agarwal, Zarko Alfirevic, Joyce Lim, Musa Kaleem, Caren Landes, M. Zulf Mughal, R. Ramakrishnan
المصدر: Bone Reports, Vol 12, Iss , Pp 100280- (2020)
بيانات النشر: Elsevier, 2020.
سنة النشر: 2020
المجموعة: LCC:Diseases of the musculoskeletal system
مصطلحات موضوعية: Antenatal, Bisphosphonates, GACI, Diseases of the musculoskeletal system, RC925-935
الوصف: Background: Generalised arterial calcification of infancy (GACI) is a rare disorder characterised by the deposition of hydroxyapatite crystals within the vessel walls. It is associated with a high mortality rate. Bisphosphonates have been used with some success in the treatment of GACI. However, there is a paucity of data on the antenatal use of bisphosphonates for GACI. In this paper, we report development of the skeletal changes suggestive of hypophosphatasia (HPP) in an infant with GACI, whose mother was treated with etidronate during pregnancy. Case report: A Caucasian infant boy had a suspected antenatal diagnosis of GACI based on the findings suggestive of calcification of the annulus of the tricuspid valve and wall of the right ventricular (RV) outflow tract and main pulmonary artery on foetal echocardiography and the genetic analysis which showed a pathogenic heterozygous mutation in ABCC6. Based on these findings, mother was started on etidronate treatment from 26 weeks of gestation. A healthy male baby was delivered at 38 weeks of gestation. Initial postnatal echocardiogram on day 1 of life was normal with good biventricular function; subtle changes suggestive of microcalcifications were detected on the CT angiography. Serum calcium, phosphate, alkaline phosphatase and renal profile were normal. Further, the serum inorganic pyrophosphate (PPi) level was significantly low. Skeletal changes suggestive of HPP were seen on the radiographs. The baby developed cardiac dysfunction on day 4 of life with evidence of ischaemic changes on electrocardiogram (ECG).Treatment with etidronate was started in view of probable evolving coronary calcifications. Despite treatment with cardiac supportive measures and bisphosphonate, he succumbed to death in the third week of life. Discussion: We believe, this is the first report of skeletal changes suggestive of HPP, arising secondary to antenatal etidronate (first generation bisphosphonate) used for the treatment of suspected GACI due to a heterozygous ABCC6 mutation.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2352-1872
Relation: http://www.sciencedirect.com/science/article/pii/S2352187220300401; https://doaj.org/toc/2352-1872
DOI: 10.1016/j.bonr.2020.100280
URL الوصول: https://doaj.org/article/468211443a98465b90e9fb5bdf6fde7a
رقم الأكسشن: edsdoj.468211443a98465b90e9fb5bdf6fde7a
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:23521872
DOI:10.1016/j.bonr.2020.100280